«Due to our prior successes in treating these patients with sorafenib and lenvatinib, patients are doing better, but they still ultimately progress, and we need additional agents with different mechanisms of action,» Brose said. (sciencedaily.com)
All in all, the researchers maintain that their results support the use of sorafenib in combination with other drugs in the treatment of multiple myeloma. (news.cision.com)
«Researchers reported a response rate of 19 percent, which is much better than the 2 percent response rate with the FDA - approved drug sorafenib (Nexavar),» Chung said. (cityofhope.org)